Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 1
Submit an article Journal homepage
422
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Novel investigational drugs mimicking exercise for the treatment of cachexia

F. PennaDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy;Interuniversity Institute of Myology, Italy
,
F. PinDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy;Interuniversity Institute of Myology, Italy
,
R. BallaròDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy;Interuniversity Institute of Myology, Italy
,
F.M. BaccinoDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy
&
P. CostelliDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy;Interuniversity Institute of Myology, ItalyCorrespondence[email protected]
Pages 63-72 | Published online: 26 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●) to readers.
  • Argilés JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14:754–762.

● One of the most complete reviews on cancer cachexia and energy metabolism alterations

  • Penna F, Baccino FM, Costelli P. Coming back: autophagy in cachexia. Curr Opin Clin Nutr Metab Care. 2014;17:241–246.
  • Tessitore L, Costelli P, Baccino FM. Pharmacological interference with tissue hypercatabolism in tumour-bearing rats. Biochem J. 1994;299:71–78.
  • Chacon-Cabrera A, Fermoselle C, Urtreger AJ, et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol. 2014;229:1660–1672.
  • Penna F, Bonetto A, Aversa Z, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle. 2015. Available from: http://doi.wiley.com/10.1002/jcsm.12050
  • Masiero E, Agatea L, Mammucari C, et al. Autophagy is required to maintain muscle mass. Cell Metab. 2009;10:507–515.
  • Penna F, Costamagna D, Pin F, et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol. 2013;182:1367–1378.
  • Carnio S, LoVerso F, Baraibar MA, et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014;8:1509–1521.
  • Li JP, Lu L, Wang LJ, et al. Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure. Clin Biochem. 2011;44:984–988.
  • Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23:507–515.
  • Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–899.
  • Walston J, Fedarko N, Yang H, et al. The physical and biological characterization of a frail mouse model. J Gerontol A Biol Sci Med Sci. 2008;63:391–398.
  • Cai D, Frantz JD, Tawa NE, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119:285–298.
  • Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011;6:e22538.
  • Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.
  • Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014;33:737–748.
  • Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758–1764.
  • Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45:1309–1318.
  • Muscaritoli M, Molfino A, Lucia S, et al. Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit Rev Oncol Hematol. 2015;94:251–259.
  • Aoyagi T, Terracina KP, Raza A, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7:17–29.
  • Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493–495.
  • Penna F, Costamagna D, Fanzani A, et al. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 2010;5:e13604.
  • He WA, Berardi E, Cardillo VM, et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. 2013;123:4821–4835.
  • Ramamoorthy S, Donohue M, Buck M. Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. Am J Physiol Endocrinol Metab. 2009;297:E392–401.
  • Prado CMM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106:1583–1586.
  • Toledo M, Penna F, Busquets S, et al. Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. PLoS One. 2014;9:e113931.
  • Shum AMY, Mahendradatta T, Taylor RJ, et al. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging. 2012;4:133–143.
  • Fontes-Oliveira CC, Busquets S, Toledo M, et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta. 2013;1830:2770–2778.
  • Julienne CM, Dumas J-F, Goupille C, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle. 2012;3:265–275.
  • Tzika AA, Fontes-Oliveira CC, Shestov AA, et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int J Oncol. 2013;43:886–894.
  • McLean JB, Moylan JS, Andrade FH. Mitochondria dysfunction in lung cancer-induced muscle wasting in C2C12 myotubes. Front Physiol. 2014;5:503.
  • White JP, Puppa MJ, Sato S, et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle. 2012;2:14.
  • Romanello V, Sandri M. Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation. Curr Hypertens Rep. 2010;12:433–439.

● A very good survey of the relation between altered mitochondria and muscle protein breakdown.

  • Varanita T, Soriano ME, Romanello V, et al. The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage. Cell Metab. 2015;21:834–844.
  • Zinna EM, Yarasheski KE. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care. 2003;6:87–93.

● This review clearly shows the effectiveness of exercise in correcting muscle wasting.

● This paper demonstrates the effect of PGC-1α modulations on mitophagy.

  • Itoh Y, Hayakawa K, Mori T, et al. Stand-up exercise training facilitates muscle recovery from disuse atrophy by stimulating myogenic satellite cell proliferation in mice. Physiol Rep. 2014;2:e12185–e12185.
  • Mangan G, Bombardier E, Mitchell AS, et al. Oestrogen-dependent satellite cell activation and proliferation following a running exercise occurs via the PI3K signalling pathway and not IGF-1. Acta Physiol. 2014;212:75–85.
  • Constantinou C, Fontes De Oliveira CC, Mintzopoulos D, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med. 2011;27:15–24.
  • Luquet S, Lopez-Soriano J, Holst D, et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 2003;17:2299–2301.
  • Wang Y-X, Zhang C-L, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004;2:e294.
  • Schuler M, Ali F, Chambon C, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4:407–414.
  • Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134:405–415.

●● The first demonstration that exercise can be mimicked by drugs.

  • Kleiner S, Nguyen-Tran V, Baré O, et al. PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function. J Biol Chem. 2009;284:18624–18633.
  • Ljubicic V, Burt M, Jasmin BJ. The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. Faseb J. 2014;28:548–568.

●● An elegant demonstration that PPARδ agonists improve muscle dystrophy.

  • Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A. 2008;105:4271–4276.
  • Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A. 2003;100:15924–15929.
  • Olson EJ, Pearce GL, Jones NP, et al. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32:2289–2294.
  • Bays HE, Schwartz S, Littlejohn T, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96:2889–2897.
  • Jahnke VE, Van Der Meulen JH, Johnston HK, et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle. 2012;2:16.
  • Wang X, Hu Z, Hu J, et al. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147:4160–4168.
  • Asp ML, Tian M, Wendel AA, et al. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer. 2010;126:756–763.
  • Asp ML, Tian M, Kliewer KL, et al. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 2011;12:957–965.
  • Shea MK, Nicklas BJ, Marsh AP, et al. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss. Obesity. 2011;19:1636–1646.
  • Castillero E, Alamdari N, Aversa Z, et al. PPARβ/δ regulates glucocorticoid- and sepsis-induced FOXO1 activation and muscle wasting. PLoS One. 2013;8:e59726.
  • Fuster G, Busquets S, Ametller E, et al. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res. 2007;67:6512–6519.
  • Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2015;14:523–531.
  • Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther. 2012;3:1.
  • Krawiec BJ, Nystrom GJ, Frost RA, et al. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am J Physiol Endocrinol Metab. 2007;292:E1555–67.
  • Sanchez AMJ, Candau RB, Csibi A, et al. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol. 2012;303:C475–85.
  • Mounier R, Théret M, Lantier L, et al. Expanding roles for AMPK in skeletal muscle plasticity. Trends Endocrinol Metab. 2015;26:275–286.
  • Tabony AM, Yoshida T, Galvez S, et al. Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension. 2011;58:643–649.
  • Diaz EC, Herndon DN, Porter C, et al. Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns. Burns. 2015;41:649–657.
  • Cetrone M, Mele A, Tricarico D. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr Diabetes Rev. 2014;10:231–237.
  • Chevalier S, Farsijani S. Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment. Appl Physiol Nutr Metab. 2014;39:643–653.
  • Um J-H, Park S-J, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59:554–563.
  • Wang B, Yang G, Liang X, et al. Grape seed extract prevents skeletal muscle wasting in interleukin 10 knockout mice. BMC Complement Altern Med. 2014;14:162.
  • Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–622.
  • Naia L, Rego AC. Sirtuins: double players in Huntington’s disease. Biochim Biophys Acta. 2015;1852:2183–2194.
  • Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253–295.
  • Cantó C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20:98–105.
  • Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690.

●● An elegant demonstration that SIRT1 is crucial for resveratrol-induced AMPK stimulation and mitochondrial function improvement.

  • Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6:759–767.
  • Lee D, Goldberg AL. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol Chem. 2013;288:30515–30526.
  • Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015;15:608–624.
  • Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122.
  • Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342.
  • Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007;26:1913–1923.
  • Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012;7:e51395.
  • Hoffmann G, Breitenbücher F, Schuler M, et al. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 2014;289:5208–5216.
  • Venkatasubramanian S, Noh RM, Daga S, et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc. 2013;2:e000042.
  • Mercken EM, Mitchell SJ, Martin-Montalvo A, et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014;13:787–796.

●● This study shows the protective effects of synthetic SIRT1 activators on aging and immobilization-induced muscle atrophy.

  • Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 2006;103:16260–5t.
  • Chan MC, Arany Z. The many roles of PGC-1α in muscle — recent developments. Metabolism. 2014;63:441–451.
  • Hindi SM, Mishra V, Bhatnagar S, et al. Regulatory circuitry of TWEAK-Fn14 system and PGC-1α in skeletal muscle atrophy program. FASEB J. 2014;28:1398–1411.
  • Kumar A, Bhatnagar S, Paul PK. TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2012;15:233–239.
  • Ruas JL, White JP, Rao RR, et al. A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell. 2012;151:1319–1331.
  • Tian M, Asp ML, Nishijima Y, et al. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39:1321–1326.
  • Jamart C, Francaux M, Millet GY, et al. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running. J Appl Physiol. 2012;112:1529–1537.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.